KYTX vs OKTA · $488.8M cap vs P/E 84, rev $1.57B
Kyverna Therapeutics, Inc. Common Stock (KYTX) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
Kyverna Therapeutics, Inc. Common Stock (KYTX) is a biotechnology company listed on NASDAQ.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
KYTX does not have a complete income-statement cache yet.
Latest reported OKTA revenue for 2026-07-31 was $1.57B. Net income was $190.0M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
KYTX currently screens at market cap $488.8M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the KYTX and OKTA stock pages for the full models.
Not investment advice.